A great example of a local company giving back to the business community: Montgomery County’s Immunomic Therapeutics, Inc. Founder Dr. Bill Hearl, recently announced the launch of the Immunomic Therapeutics Cancer Discovery Incubator. According to the video announcement posted on YouTube, the incubator “will enable and accelerate ventures, with the capacity for measurable change in oncology health. The goal is to empower the beneficiary to conduct proof-of-concept experiments and ultimately, attract funding partnerships, and fuel growth.” Check out the complete video for further information.
Join us for an evening of food, drink, and revelry as we celebrate moving into our new prototyping and manufacturing facility! Tour the new offices and check out the workshop. See what all the buzz is about.
We’ll also have some entertainment for your inner geek. Get an introduction to some of the tools or test your robot driving skills with the “House Bots” from the Baltimore Robotics Center.
Rexahn Pharmaceuticals, Inc. (NYSE: RNN) announced that it has been issued a patent from the United States Patent and Trademark Office (USPTO) covering RX-21101 for the targeted delivery of docetaxel directly into cancer tumor cells using a nano-polymer conjugate technology.
Johns Hopkins University has licensed a technology that tests for a marker of cancer’s susceptibility to immunotherapy to Personal Genome Diagnostics (PGDx), a leading provider of advanced cancer genome testing products and services.
The technology tests for microsatellite instability (MSI), which occurs when cells have a defect in the ability to repair the mistakes that naturally occur when cellular DNA is copied. Tumor cells with MSI typically have many more mutations than other tumor cells and are more often successfully treated with new immuno-oncology drugs such as PD-1 checkpoint inhibitors.
Altimmune, Inc., a clinical stage immunotherapeutic company, today announced that a poster detailing the design and preclinical evaluation of its HepTcell immunotherapeuticfor the treatment of chronic hepatitis B infection will be presented at the 2017 Keystone Symposia Conference taking place October 25 – 29, 2016 in London.
“Chemistry is the study of matter,” Walter White once opined on Breaking Bad. “But I prefer to see it as the study of change.”
If you take matter (in this case, brick and mortar real estate) and you factor in change (the rising price of this matter), what you’re left with are fewer places to study heady topics like chemistry.
Northrop Grumman Corporation (NOC) and the bwtech@UMBC Cyber Incubator announced today that two more cyber startups – one representing the first international company to participate – have graduated from the Northrop Grumman Cync program. iWebGate of Perth, Australia and Light Point Security of Baltimore have completed the Cync scholarship program.
Bing Yao, PhD, Head of Respiratory, Inflammation and Autoimmunity at MedImmune, spoke with Healio Rheumatology about MedImmune’s collaboration with the University of California at San Francisco, techniques to quantify biomarkers and MedImmune’s role in treating rheumatologic patients.
Entrepreneur, the magazine that celebrates small business, recently released a list of what they consider to be the 360 best small businesses America has to offer. And wouldn’t you know — some of #dctech’s own were among the companies named.
The list is not meant to showcase only companies that are growing really fast (we see you, Inc.) — it’s more of a congratulations to companies “that keep all their parts growing in harmony.” As such, each company on the list has been evaluated according to the metrics of impact, innovation, growth and leadership.
Kevin Plank’s underdog story has become synonymous with Baltimore — the city his company Under Armour calls home.
Now his investment company, Plank Industries, is looking to rebuild an entire area of the city. Billions of dollars will be poured into Port Covington in one of the largest urban redevelopment projects in the country, which will include housing, retail and an entrepreneurial ecosystem.
Maryland Stem Cell Research Commission announced today the launch of Accelerating Cure, a new initiative to support regenerative medicine and cell therapy technologies moving from research to commercialization and finally to clinical trials. Accelerating Cure will fund close to $9 million with its five programs to address the different stages the technologies need to go through. The Commission also announced that Dr. Amritha Jaishankar joined the team as the Award Manager for the Maryland Stem Cell Research Fund.
Reston-based telemedicine provider Avizia Inc. raised $6 million in Series A funding, amping up a fundraising round we reported earlier this year to a total of $17 million.
Biotech venture capital is supposed to be the highest-risk/highest-reward type of investment there is. But many biotech VCs are actually pretty conservative, hesitant to wager on edgy science that might take a decade to pay off.
The Global Competitiveness Report assesses the competitiveness landscape of 138 economies, providing insight into the drivers of their productivity and prosperity. Switzerland, Singapore and the United States remain the three world’s most competitive economies.
Amgen Europe GmbH, an affiliate of Amgen Inc, has invested in an Israel-based digital health incubator, eHealth Ventures, to serve patients by driving innovation and sustainable healthcare through technology discovery.
“This addition will provide a new strategic element to our screening process and build significant value to our portfolio companies. Having Amgen on board will deliver invaluable assets and know-how in many of the digital health innovation aspects, including market input, commercialisation of R&D, business modeling, go-to-market strategies and more,” said Talor Sax, chief executive officer, eHealth Ventures Incubator.
The goals for economic development have long focused on expanding opportunities for citizens. With greater pressure to demonstrate impact, states have embraced the collection and reporting of performance indicators. However, as the economy continues to change, economic development goals become more nuanced. Consequently, state economic development leaders seek to improve the indicators they use to measure the effectiveness of their incentive programs. This white paper describes common indicators in use, pros and cons of the two most common types of indictors: those representing jobs and investment. The white paper also offers guidance on the process for improving and expanding the slate of indicators states can deploy to evaluate their efforts.
New York biotech has historically lagged behind more established life sciences hubs like Boston and San Francisco, but collaborations between its research institutions have helped the city start to move forward. Another step in that direction was taken this morning, with the launch of what’s being called Bridge Medicines.
Cori Bargmann’s new job description includes “to help cure, prevent or manage all diseases by the end of the century.” That’s quite a lofty goal.
Bargmann is a neuroscientist and president of science for the Chan Zuckerberg Initiative, the joint venture of pediatrician Priscilla Chan and Facebook co-founder Mark Zuckerberg. The couple pledged $3 billion to solve major medical problems by helping scientists and engineers collaborate long term, over 25, 50, even 80 years.
This table shows the “sticker prices” — published tuition and required fees — at more than 3,000 colleges and universities for the 2016-17 academic year. Click the institutions’ names to see historical data back to 1998.
The Open Data Science Symposium is open to the public and will be available through a webcast.
Big Data is an underutilized resource for innovation and discovery in biomedical research and the NIH is committed to unleashing its full potential by making it an open and easily accessible resource. The Open Data Science Symposium will feature discussions with the leaders in big data, open science, and biomedical research while also showcasing the finalists of the Open Data Science Prize, a worldwide competition to harness the innovative power of open data.
Please Register for the Open Data Science Symposium by November 18, 2016.
BioBuzz and Elite Sponsor the Institute for Bioscience and Biotechnology Research (IBBR) are excited to announce a special event that lands right in the middle of the Oktoberfest season. Flying Dog Brewery will be our guest as we bring together the worlds of biotech and beer to show how closely related they really are. We are proud to have BioBuzz Double Helix Sponsors CRB and BREP along with Azzur IT as Co-Sponsors for this event.
Before the general networking begins, Flying Dog CEO, Jim Caruso, and COO/Head Brew Master, Matt Brophy will be on the IBBR Auditorium stage from 5:00 p.m. – 6:00 p.m. to speak about the company and everything that goes into the process of brewing their beer.
Bringing entrepreneurs from all around together at one place! This is the premier event in Maryland showcasing all the resources to help entrepreneurs to learn, connect and be inspired.
The information contained in this website and newsletters is for general information purposes only. The information is provided by BioHealth Innovation via its newsletters, but not written or endorsed in any way by BioHealth Innovation unless otherwise noted. While we endeavor to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
